283 related articles for article (PubMed ID: 22440500)
1. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry.
Micari A; Cioppa A; Vadalà G; Castriota F; Liso A; Marchese A; Grattoni C; Pantaleo P; Cremonesi A; Rubino P; Biamino G
JACC Cardiovasc Interv; 2012 Mar; 5(3):331-8. PubMed ID: 22440500
[TBL] [Abstract][Full Text] [Related]
2. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry.
Micari A; Cioppa A; Vadalà G; Castriota F; Liso A; Marchese A; Grattoni C; Pantaleo P; Cremonesi A; Rubino P; Biamino G
JACC Cardiovasc Interv; 2013 Mar; 6(3):282-9. PubMed ID: 23517840
[TBL] [Abstract][Full Text] [Related]
3. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Micari A; Vadalà G; Castriota F; Liso A; Grattoni C; Russo P; Marchese A; Pantaleo P; Roscitano G; Cesana BM; Cremonesi A
JACC Cardiovasc Interv; 2016 May; 9(9):950-6. PubMed ID: 27151609
[TBL] [Abstract][Full Text] [Related]
4. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
[TBL] [Abstract][Full Text] [Related]
5. A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: acute and midterm results.
Micari A; Cioppa A; Vadalà G; Stabile E; Castriota F; Pantaleo P; Grattoni C; Cremonesi A; Marchese A; Rubino P; Biamino G
EuroIntervention; 2011 May; 7 Suppl K():K77-82. PubMed ID: 22027734
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
7. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
[TBL] [Abstract][Full Text] [Related]
8. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study.
Laird JR; Yeo KK; Rocha-Singh K; Das T; Joye J; Dippel E; Reddy B; Botti C; Jaff MR
Catheter Cardiovasc Interv; 2012 Nov; 80(5):852-9. PubMed ID: 22422738
[TBL] [Abstract][Full Text] [Related]
9. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
10. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
Dake MD; Scheinert D; Tepe G; Tessarek J; Fanelli F; Bosiers M; Ruhlmann C; Kavteladze Z; Lottes AE; Ragheb AO; Zeller T;
J Endovasc Ther; 2011 Oct; 18(5):613-23. PubMed ID: 21992630
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
Teichgräber U; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Thieme M; Blessing E; Treitl M; Lichtenberg M; von Flotow P; Vogel B; Werk M; Riambau V; Wienke A; Lehmann T; Sixt S
Trials; 2016 Oct; 17(1):528. PubMed ID: 27793175
[TBL] [Abstract][Full Text] [Related]
13. Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.
Herten M; Torsello GB; Schönefeld E; Imm B; Osada N; Stahlhoff S
J Vasc Surg; 2015 Feb; 61(2):394-9. PubMed ID: 25307133
[TBL] [Abstract][Full Text] [Related]
14. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
[TBL] [Abstract][Full Text] [Related]
15. Acotec Drug-Coated Balloon Catheter: Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial.
Jia X; Zhang J; Zhuang B; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W
JACC Cardiovasc Interv; 2016 Sep; 9(18):1941-9. PubMed ID: 27659572
[TBL] [Abstract][Full Text] [Related]
16. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
Mwipatayi BP; Perera K; Daneshmand A; Daniel R; Wong J; Thomas SD; Burrows SA
Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Biodegradable Igaki-Tamai Scaffold After Drug-Eluting Balloon Treatment of De Novo Superficial Femoral Artery Lesions: The GAIA-DEB Study.
Werner M; Schmidt A; Scheinert S; Banning-Eichenseer U; Ulrich M; Bausback Y; Steiner S; Scheinert D
J Endovasc Ther; 2016 Feb; 23(1):92-7. PubMed ID: 26620399
[TBL] [Abstract][Full Text] [Related]
18. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
[TBL] [Abstract][Full Text] [Related]
19. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Tran K; Ullery BW; Kret MR; Lee JT
Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial.
Werk M; Langner S; Reinkensmeier B; Boettcher HF; Tepe G; Dietz U; Hosten N; Hamm B; Speck U; Ricke J
Circulation; 2008 Sep; 118(13):1358-65. PubMed ID: 18779447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
